[Biologics and cardiovascular risk].
Over the course of the last decade, biologic response modifiers (biologics) have significantly broadened the therapeutic armamentarium in clinical rheumatology. In addition to their impressive efficacy, they have also received considerable attention regarding their adverse effects. In contrast to the risk of severe infections and malignancies, the cardiovascular risk of these drugs has provoked less vigilance. This article reviews the current data on the cardiovascular effects and adverse effects of biologics.
Tarner
I H
IH
Lehrstuhl für Innere Medizin mit Schwerpunkt Rheumatologie der Justus-Liebig-Universität Gießen, Abteilung für Rheumatologie, klinische Immunologie, Osteologie und Physikalische Medizin, Kerckhoff-Klinik Bad Nauheim, Deutschland. ingo.h.tarner@innere.med.uni-giessen.de
Müller-Ladner
U
U
Hamm
C
C
D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001688:Biological Products / Q000009:adverse effects* / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D006801:Humans; D012216:Rheumatic Diseases / Q000150:complications / Q000188:drug therapy*
D018501:Antirheumatic Agents; D001688:Biological Products